Philadelphia’s Spark Therapeutics is going through a “fundamental reorganization” by its owner, Swiss pharmaceutical giant Roche, which has written off the regional biotech leader as a financial loss ...

Beqvez brings an inauspicious ending to a gene therapy that got its start more than a decade ago in the labs of Spark Therapeutics in Philadelphia. Pfizer's disclosure Friday that it is ending ...

In connection with Spark’s overhaul, Roche will incur approximately $2.4 billion in goodwill impairment costs. This sum takes ...